Diversified Consumer Services
Company Overview of Yale University
Yale University is an independent research and educational institution that offers programs, departments, schools, centers, museums, and affiliated organizations. The university offers graduate and professional courses in art, architecture, divinity, drama, engineering, music, forestry and environmental studies, law, management, and medicine. Yale University was founded in 1701 and is based in New Haven, Connecticut. The university has endowment assets worth $10.7 billion.
206 Elm Street
New Haven, CT 06511-9992
Founded in 1701
Key Executives for Yale University
Vice President of New Haven and State Affairs
Vice President for Finance & Business Operations
Program Director of Center for Business and the Environment
Vice President and Secretary
Compensation as of Fiscal Year 2013.
Yale University Key Developments
Evotec AG and Yale University to Collaborate on Cancer Therapy
Dec 17 13
Evotec AG announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine. The objective of this collaboration is to identify novel mechanisms, targets and compounds that have the potential to interfere with DNA repair. DNA repair mechanisms allow cancer cells to cope with extensive genome rearrangements as well as to escape conventional radio- and chemotherapy and thus have potential applications in many cancer indications. This is the first collaboration to be announced as part of Evotec's open innovation alliance with Yale University. TargetDBR is based on systematic cell screens designed to identify DNA repair inhibitors and their mechanisms of action. The application of Evotec's high-content cellular screening platforms allied to chemoproteomics-based target deconvolution will enable the identification not only of novel DNA repair inhibitors but also of novel tractable targets in DNA repair pathways. The initial focus will be on increasing the effectiveness of glioblastoma brain tumour treatments but it is expected that the DNA repair inhibitors will also find application in many other cancer types. Yale and Evotec will collaborate in a highly integrated fashion and share potential commercial rewards.
Novogen Limited and Yale University Announce the Establishment of New Joint Venture Dedicated to the Development of Chemotherapy Strategies to Fight Ovarian Cancer
Nov 6 13
Novogen Limited and Yale University announced the establishment of a new joint venture dedicated to the development of chemotherapy strategies to fight ovarian cancer. The joint venture company is CanTx Inc. and is based in New Haven, Connecticut. Novogen owns 85% of the new company. The joint venture brings together two fundamental complementary resources required to combat ovarian cancer. In the case of Novogen it is a drug technology platform capable for the first time of killing the full range of cells within an ovarian cancer at clinically meaningful doses, but most importantly, ovarian cancer stem cells. In the case of Yale, it is the in vitro and in vivo test systems capable of evaluating the clinical potential of those drugs. The involvement of Yale also ensures access to world-class clinical facilities and will expedite the move from the bench into the clinic. CanTx R&D will be centered at the laboratories of Professor Gil Mor of Yale Medical School. Professor Mor is the first researcher in the world to isolate ovarian cancer stem cells: those cells responsible for ovarian tumor growth initially and then tumor recurrence following chemotherapy. Under this joint venture arrangement, Novogen retains full ownership of its drug technology intellectual property (IP) and will grant CanTx access to that IP for drug development purposes only. Novogen separately will continue to exploit the same IP for a range of other clinical indications including glioblastoma, along with its newly-acquired anti-tropomyosin drug technology. Current chemotherapy unfortunately only does half the job. It is reasonably effective at killing the predominant somatic cancer cells, but by not killing the cancer stem cells. Around 70% of patients who respond to first round chemotherapy will eventually experience tumor recurrence.
Virginia Chapman to Serve as Next Director of Sustainability at Yale, Effective Nov. 18, 2013
Oct 18 13
Virginia Chapman, who has worked during her career at Yale to "green" the campus, will serve as the next director of sustainability at Yale, effective Nov. 18, 2013. In her current role as director of facilities sustainable initiatives, Ginger has provided leadership within the Office of Facilities on a number of key strategies including sustainable building design and construction, the development of the Sustainability Supplement to the Framework for Campus Planning and the Sustainable Stormwater Management Plan, as well as more sustainable land use practices.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|